` BONEX (Bonesupport Holding AB) vs OMX Stockholm 30 Comparison - Alpha Spread

BONEX
vs
OMX Stockholm 30

Over the past 12 months, BONEX has significantly outperformed OMX Stockholm 30, delivering a return of 35% compared to the OMX Stockholm 30's 5% drop.

Stocks Performance
BONEX vs OMX Stockholm 30

Loading
BONEX
OMX Stockholm 30
Add Stock

Performance Gap
BONEX vs OMX Stockholm 30

Loading
BONEX
OMX Stockholm 30
Difference

Performance By Year
BONEX vs OMX Stockholm 30

Loading
BONEX
OMX Stockholm 30
Add Stock

Competitors Performance
Bonesupport Holding AB vs Peers

OMX Stockholm 30
BONEX
ABBV
AMGN
GILD
VRTX
Add Stock

Bonesupport Holding AB
Glance View

Economic Moat
Wide
Market Cap
21B SEK
Industry
Biotechnology

Bonesupport Holding AB, a Swedish company, has carved a niche for itself in the intricate world of orthopedic treatments and regenerative medicine. Founded in 1999, the company's journey is rooted in innovation and development of injectable bio-ceramic bone graft substitutes, primarily aimed at addressing bone voids and other skeletal maladies. The cornerstone of their business is the proprietary CERAMENT platform, which combines biocompatible, synthetic materials with a unique ability to promote bone healing and integration. By offering solutions that are resorbable and can enhance the regrowth of natural bone, Bonesupport targets clinicians and professionals in orthopedics, trauma, and spine surgery, offering them alternatives to traditional bone grafting methods. The company's products, including CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V, differentiate themselves by also being antibiotic-eluting—allowing for the simultaneous treatment of bone diseases and infection mitigation. Bonesupport's revenue models revolve around both direct sales and leveraging distribution partnerships in key markets, including Europe, the United States, and emerging regions. The company channels substantial investments into research and development, seeking to broaden the clinical applications of their technologies thus driving adoption in the market. They benefit from a growing interest in minimally invasive treatments among healthcare providers, who aim to enhance patient outcomes while also controlling costs. By continuing to expand its product portfolio and advancing clinical evidence, Bonesupport maintains a competitive edge in skeletal health, translating innovation and efficacy into profitability and market growth. This strategic pursuit of advanced bone treatment technologies underscores their role in transforming standard medical practices, ensuring they remain at the forefront of bone health solutions.

BONEX Intrinsic Value
270.47 SEK
Overvaluation 14%
Intrinsic Value
Price
Back to Top